Indivior | INDV



Peers Price Chg Day Year Date
Kyowa Hakko Kirin 2,034.50 -2.00 -0.10% -29.35% Feb/20
AstraZeneca 11,704.00 -84.00 -0.71% 14.70% Feb/19
Glaxosmithkline 36.54 -0.07 -0.19% -13.04% Feb/19
Halozyme Therapeutics 57.77 -0.13 -0.22% 60.47% Feb/19
Indivior 868.00 16.00 1.88% -33.94% Feb/19
J&J 157.94 2.96 1.91% 0.05% Feb/19
Eli Lilly 866.50 9.07 1.06% 14.67% Feb/19
Merck 85.56 2.31 2.77% -32.83% Feb/19
Novartis 107.04 0.45 0.42% 4.21% Feb/19
Pfizer 25.86 0.30 1.17% -6.27% Feb/19
Sanofi 53.55 -0.39 -0.72% 14.30% Feb/19
Supernus Pharmaceuticals 33.52 -6.23 -15.67% 19.50% Feb/19

Indivior PLC traded at 868.00 this Wednesday February 19th, increasing 16.00 or 1.88 percent since the previous trading session. Looking back, over the last four weeks, Indivior gained 12.01 percent. Over the last 12 months, its price fell by 33.94 percent. Looking ahead, we forecast Indivior PLC to be priced at 944.29 by the end of this quarter and at 905.73 in one year, according to Trading Economics global macro models projections and analysts expectations.

Indivior PLC is a pharmaceutical company. The Company is engaged in developing medicines to treat substance use disorders (SUD), serious mental illnesses, and opioid overdose. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder, and co-morbidities, including schizophrenia. Its core products include SUBLOCADE (buprenorphine extended release) monthly injection; SUBOXONE Film (buprenorphine and naloxone sublingual film); SUBOXONE Tablet (buprenorphine and naloxone sublingual tablets), and SUBUTEX Tablet (buprenorphine sublingual tablets). Its products for the treatment of opioid disorders (OUD) are OPVEE (nalmefene) nasal spray for opioid overdose reversal, and PERSERIS (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults in the United States. Its portfolio of products is available in 37 countries.